DOP073: Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided Ulcerative Colitis patients with moderate-to-severe diseaseECCO'17 Barcelona 2017
1
DOP074: Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in Ulcerative Colitis patientsECCO'17 Barcelona 2017
1
DOP075: Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: Subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn' DiseaseECCO'17 Barcelona 2017
1
DOP076: A Phase 2B, multicenter, randomised, placebo-controlled dose-ranging trial of peficitinab, an OralL JAK Inhibitor, in patients with moderately to severely active Ulcerative ColitisECCO'17 Barcelona 2017
1
DOP079: The role of intestinal transplant in patients with complicated Inflammatory Bowel Disease (IBD): The Cambridge experienceECCO'17 Barcelona 2017
1
DOP080: Low viral richness at baseline in ulcerative Ulcerative Colitis associated with faecal microbiota transplantation successECCO'17 Barcelona 2017
1
DOP084: Peripheral T cell repertoire reconstitution in Crohn’s Disease patients undergoing autologous HSCTECCO'17 Barcelona 2017
1
DOP086: Macrophages from Crohn’s Disease patients showed a defect to control adherent- invasive E. coli replication influenced by genetic host factorsECCO'17 Barcelona 2017
1
DOP088: Somatic and visceral hypersensitivity associated to acute intestinal inflammation are absent in sigma 1 receptor knockout miceECCO'17 Barcelona 2017
1
DOP089: PTPN2 controls intestinal inflammation and promotes Colitis-associated tumour formation via control of inflammasome activation and IL-1alpha releaseECCO'17 Barcelona 2017
1
DOP090: The α7 nicotinic acetylcholine receptor agonist GTS-21 attenuate DSS-induced Colitis by improving intestinal mucosal barrier functionECCO'17 Barcelona 2017
1
Endoscopic and imaging features of CD, intestinal TB, 2nd ECCO-AOCC Forum: Learning from the Masters 2017
1